Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV16 E7 DNA vaccination in HPV-related squamous cell cancer
NL-OMON38905Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2013
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TTFC-E7SH in Human papillomavirus-positive squamous cell carcinoma, cervical squamous cell carcinoma (CSCC), penile squamous cell carcinoma (PSCC) and 3 more (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Toxicity of TTFC-E7SH, Toxicity of prime-boost vaccine and 2 more. Planned start Jul 2013; status: withdrawn.
02
Drugs
TTFC-E7SH
03
Conditions
Human papillomavirus-positive squamous cell carcinomacervical squamous cell carcinoma (CSCC)penile squamous cell carcinoma (PSCC)vaginal squamous cell carcinoma (SCCV)vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON38905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38905.